Table 2.
Relevant genotypes-based pharmacogenomics relationships between HLA alleles and cutaneous adverse reactions.
| Genotypes | SCARs | cADRs |
|---|---|---|
| HLA-A*02:07 | TEN in Japanese population (24) | Zonisamide-induced SJS/TEN in Japanese population (18); Lamotrigine-induced cADRs in Thai patients (21); Clarithromycin-induced cADRs in Chinese Patients (25); Tetanus-induced exanthematous drug eruptions in the Han Chinese population (16) |
| HLA-B*46:01 | - | Carbamazepine (CBZ) -induced SJS/TEN in Chinese Population (19); Phenytoin (PHT) -induced cutaneous ADR in Thai patients (20); |
| HLA-C*01:02 | - | Methazolamide-induced SJS/TEN in Han Chinese (26); |
| HLA-C*03:04 | - | Co-trimoxazole (CTX) -induced SJS/TEN and DRESS in Thai (15); Cold Medicine (CM)-induced SJS/TEN with Severe Ocular Complications (SOC) in the Korean population (27); |
| HLA-DQB1*03:01 | Herpes-associated EM in Caucasian (23) | - |
| HLA-DQB1*03:03 | - | Carbamazepine (CBZ)-induced SJS/TEN among Han individuals from northeastern China (28) |
| HLA-DRB1*09:01 | - | Allopurinol-induced hypersensitivity in Asian (PharmGKB) |
| HLA-DRB1*12:02 | - | Co-trimoxazole induced cADRs in Thai patients (29); |
| Acetaminophen-induced SJS/TEN with severe ocular complications (SOC) in Japanese individuals (30) |
HLA genotypes presented in this table were chosen from the HLA sequencing results of our patient.